Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting. - Saha S; Gerdtham UG; Sjödahl G; Häggström C; Catto JWF; Kelly JD; Ullén A; Holmberg L; Liedberg F (Frontiers in oncology, 2025)